Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
58 studies found for:    "Carcinoid syndrome"
Show Display Options
RSS Create an RSS feed from your search for:
"Carcinoid syndrome"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Withdrawn Study of Panitumumab in the Treatment of Carcinoid Syndrome
Condition: Carcinoid Syndrome
Intervention: Drug: Panitumumab
2 Completed Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome
Condition: Symptoms of Carcinoid Syndrome
Interventions: Drug: Low Dose LX1606 - Day 1 (start);   Drug: Mid-low dose LX1606 - Day 15 (start);   Drug: Mid-high dose LX1606 - Day 29 (start);   Drug: High dose LX1606 - Day 43 (start);   Drug: 4-Week LX1606 Open Label Dose Extension;   Drug: 72-Week LX1606 Open Label Dose Extension
3 Terminated Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
Condition: Malignant Carcinoid Syndrome
Interventions: Drug: lanreotide Autogel (somatostatin analogue);   Drug: Sandostatin long acting release (LAR) Depot (somatostatin analogue)
4 Completed Effects of Serotonin Excess on Bone in Carcinoid Syndrome
Condition: Carcinoid Syndrome
Intervention:
5 Completed Telotristat Etiprate for Carcinoid Syndrome Therapy
Condition: Carcinoid Syndrome
Interventions: Drug: Telotristat etiprate tablets (250 mg);   Drug: Placebo
6 Terminated Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
Condition: Carcinoid Syndrome
Intervention: Drug: Octreotide
7 Completed
Has Results
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
Condition: Carcinoid Syndrome
Interventions: Drug: Somatuline Depot (lanreotide);   Drug: placebo
8 Terminated
Has Results
Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
Condition: Carcinoid Syndrome
Intervention: Drug: BIM 23A760
9 Completed TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
Condition: Carcinoid Syndrome
Interventions: Drug: Telotristat etiprate tablets (250 mg);   Drug: Placebo tablets
10 Completed A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
Condition: Neuroendocrine Tumour (NET) With Carcinoid Syndrome
Intervention:
11 Active, not recruiting Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Condition: Carcinoid Syndrome
Intervention: Drug: Telotristat etiprate tablets (250 mg)
12 Completed Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
Condition: Carcinoid Syndrome
Interventions: Drug: Low Dose LX1606 Part 1;   Drug: Mid-Low Dose LX1606 Part 1;   Drug: Mid-High Dose LX1606 Part 1;   Drug: High Dose LX1606 Part 1;   Drug: Part 2 LX1606 Expanded Cohort;   Drug: Placebo;   Drug: LX1606 Open Label Dose Extension;   Drug: LX1606 Open Label Extension 2;   Drug: LX1606 Open Label Extension 3
13 Completed An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males
Condition: Carcinoid Syndrome
Intervention: Drug: 500 mg [14C]-LX1606
14 Terminated
Has Results
P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
Condition: Neuroendocrine Carcinoma
Intervention: Drug: Octreotide LAR
15 Completed Azilect + Antidepressant Chart Review
Condition: Serotonin Syndrome
Interventions: Drug: Group R+AD Rasagiline + Antidepressant;   Drug: Group R Rasagiline;   Drug: Group AD Anti-PD + Antidepressant
16 Completed
Has Results
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
Conditions: Carcinoid Tumor;   Malignant Carcinoid Syndrome
Interventions: Drug: Octreotide;   Drug: Placebo;   Drug: Everolimus
17 Completed Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Lung Cancer
Interventions: Biological: recombinant interferon alfa;   Drug: fluorouracil
18 Completed
Has Results
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
Condition: Carcinoid Tumors
Intervention: Drug: Pasireotide (SOM230)
19 Withdrawn Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Carcinoma
Interventions: Drug: octreotide acetate;   Drug: vatalanib;   Procedure: anti-cytokine therapy;   Procedure: antiangiogenesis therapy;   Procedure: biological therapy;   Procedure: endocrine therapy;   Procedure: enzyme inhibitor therapy;   Procedure: growth factor antagonist therapy;   Procedure: hormone therapy;   Procedure: protein tyrosine kinase inhibitor therapy;   Procedure: somatostatin analogue therapy
20 Completed Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors
Conditions: Metastatic Gastrointestinal Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Regional Gastrointestinal Carcinoid Tumor
Interventions: Biological: PEG-interferon alfa-2b;   Biological: bevacizumab;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.